Lonza’s Michael De Marco emphasizes that early tox milestones strengthen investor confidence, support funding decisions, and reduce development risk for emerging biotechs.
Michael De Marco
Advertisement
Michael De Marco, PhD, is vice president of Commercial Development, Integrated Biologics, at Lonza.
Articles by Michael De Marco
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
2
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
3
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
4
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
5